No Data
Optimistic Outlook on Relmada Therapeutics: Analyst Predicts Success for REL-1017 in Phase 3 Trials
Relmada Jumps as Jefferies Upgrades on a Potential Turnaround Story
Jefferies Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $13
Relmada Therapeutics Analyst Ratings
Express News | Relmada Therapeutics Inc : Jefferies Raises Target Price to $13 From $3.5
Express News | Relmada Therapeutics Inc : Jefferies Raises to Buy From Hold